These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7291270)

  • 1. Antagonism of the behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) and quipazine by metergoline.
    Commissaris RL; Rech RH
    Pharmacol Biochem Behav; 1981 Oct; 15(4):659-62. PubMed ID: 7291270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists.
    Mokler DJ; Commissaris RL; Warner MR; Rech RH
    J Pharmacol Exp Ther; 1983 Dec; 227(3):557-62. PubMed ID: 6655557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone alters the effects of LSD, DOM and quipazine on operant behavior of rats.
    Mokler DJ; Commissaris RL; Henck JW; Rech RH
    Pharmacol Biochem Behav; 1984 Sep; 21(3):333-7. PubMed ID: 6593750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotransmitter basis of the behavioral effects of hallucinogens.
    Rech RH; Commissaris RL
    Neurosci Biobehav Rev; 1982; 6(4):521-7. PubMed ID: 6817241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the behavioral effects of 2,5-dimethoxy-4-methyl-amphetamine (DOM) by pretreatment with p-chlorophenylalanine.
    Commissaris RL; Lyness WH; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Oct; 13(4):605-8. PubMed ID: 6449015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM) and d-amphetamine on operant responding in control and 6-hydroxydopamine-treated rats.
    Commissaris R; Lyness WH; Cordon JJ; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Nov; 13(5):621-6. PubMed ID: 7443731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclazocine disruption of operant behavior is antagonized by naloxone and metergoline.
    Henck JW; Mokler DJ; Commissaris RL; Rech RH
    Pharmacol Biochem Behav; 1983 Jan; 18(1):41-5. PubMed ID: 6828536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential antagonism by metergoline of the behavioral effects of indolealkylamine and phenethylamine hallucinogens in the rat.
    Commissaris RL; Lyness WH; Moore KE; Rech RH
    J Pharmacol Exp Ther; 1981 Oct; 219(1):170-4. PubMed ID: 6793709
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of intracranial administration of hallucinogens on operant behavior in the rat. II. 2,5-Dimethoxy-4-methylamphetamine (DOM).
    Mokler DJ; Stoudt KW; Sherman LC; Rech RH
    Pharmacol Biochem Behav; 1987 Nov; 28(3):327-34. PubMed ID: 3685066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of metergoline with diazepam, quipazine, and hallucinogenic drugs on a conflict behavior in the rat.
    Commissaris RL; Rech RH
    Psychopharmacology (Berl); 1982; 76(3):282-5. PubMed ID: 6808551
    [No Abstract]   [Full Text] [Related]  

  • 12. Clozapine blocks disruptive and discriminative stimulus effects of quipazine.
    Friedman RL; Sanders-Bush E; Barrett RL
    Eur J Pharmacol; 1984 Oct; 106(1):191-3. PubMed ID: 6529966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metergoline and quipazine on locomotor activity of rats in novel and familiar environments.
    Beninger RJ
    Pharmacol Biochem Behav; 1984 May; 20(5):701-5. PubMed ID: 6739514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism by ketanserin of the behavioral effects of quipazine but not l-5-hydroxytryptophan in squirrel monkeys.
    Witkin JM; Brady LS; Barrett JE
    Psychopharmacology (Berl); 1988; 94(3):302-5. PubMed ID: 3128804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and neuropharmacological analysis of amphetamine and 2,5-dimethoxy-4-methylamphetamine in rats.
    Tilson HA; Baker TG; Chamberlain JH
    Psychopharmacologia; 1975 Nov; 44(3):229-39. PubMed ID: 1208759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5HT2 antagonist pirenperone reverses disruption of FR-40 by hallucinogenic drugs.
    Mokler DJ; Stoudt KW; Rech RH
    Pharmacol Biochem Behav; 1985 May; 22(5):677-82. PubMed ID: 3859879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central 5-hydroxytryptamine and the effects of hallucinogens and phenobarbital on operant responding in rats.
    Commissaris RL; Lyness WH; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1981 May; 14(5):595-601. PubMed ID: 7243838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral interactions of opioid agonists and antagonists with serotonergic systems.
    Rech RH; Mokler DJ; Commissaris RL; Henck JW
    NIDA Res Monogr; 1984 Mar; 49():179-84. PubMed ID: 6434957
    [No Abstract]   [Full Text] [Related]  

  • 19. Nefazodone in the rat: mimicry and antagonism of [-]-DOM-induced stimulus control.
    Eckler JR; Rabin RA; Winter JC
    Pharmacol Biochem Behav; 2003 May; 75(2):405-10. PubMed ID: 12873632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) on schedule-controlled behavior.
    Harris RA; Snell D; Loh HH
    Pharmacol Biochem Behav; 1977 Oct; 7(4):307-10. PubMed ID: 928488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.